Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation [0.03%]
治疗带有KRAS G12C突变的非小细胞肺癌药物sotorasib
Xinting Zheng,Jiamin Luo,Wei Liu et al.
Xinting Zheng et al.
Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug Administration (FDA), as a second-line treatment for locally advanced or metastatic non-sma...
Angelina Labib,Ashley Vander Does,Gil Yosipovitch
Angelina Labib
Atopic dermatitis (AD) is a common inflammatory skin disease that has emerging treatments targeting the underlying immunological mechanism. Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to sympt...
Jack D Sobel
Jack D Sobel
Worldwide, effective management of vulvovaginal candidiasis (VVC) continues to serve as a major therapeutic goal with numerous unmet drug treatment challenges. After 3 decades of azole drug dominance, with few recent new antifungal agents a...
An update on romiplostim for treatment of acute radiation syndrome [0.03%]
关于重组血小板生成素受体激动剂Romiplostim治疗急性辐射综合征的最新研究进展
Vijay K Singh,Thomas M Seed
Vijay K Singh
Detonation of an improvised nuclear weapon, or a radiological dispersal device by terrorists, or an unintended radiological/nuclear accident in populated areas would result in a mass casualty scenario with radiation exposures of different s...
Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances [0.03%]
关于复发/难治性多发性骨髓瘤的Idecabtagene vicleucel：近期研究进展综述
Wei Tu,Yajuan Xiao,Yadong Wang et al.
Wei Tu et al.
The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies, coupled with autologous stem cell transplantatio...
Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia [0.03%]
重组人第七因子(Eptacog β，索非库单抗)治疗甲型血友病疗效及安全性系统评价和 meta 分析
Nathan Watson,Hanny Al-Samkari
Nathan Watson
Hemophilia A and B are X-linked hereditary bleeding disorders due to factor VIII (FVIII) or factor IX (FIX) deficiency, respectively. Major advancements have been made in the care of patients with hemophilia, yet the development of inhibito...
Kenichi Nishie,Seiichi Sato,Masayuki Hanaoka
Kenichi Nishie
Cancer anorexia-cachexia syndrome is a multifactorial condition characterized by significant weight loss due to muscle loss. It is associated with functional impairment, changes in body composition and nutritional disorders. Ghrelin recepto...
Xiang-Yu Ma,Min Zhao,Yi-Dong Li et al.
Xiang-Yu Ma et al.
Ibrutinib, an oral small-molecule targeted drug, has been the first Bruton tyrosine kinase (BTK) inhibitor in the world to be approved for the market. It works by regulating cell proliferation, apoptosis and migration, and has been proven t...
Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease [0.03%]
loteprednol etabonate眼用凝胶制剂治疗干眼炎急性期炎症反应短期疗效观察
David M Paton
David M Paton
Loteprednol etabonate is a soft corticosteroid that is rapidly deactivated after reaching the general circulation, displaying good local activity and a high therapeutic index without inducing systemic side effects. In 2021, Kala Pharmaceuti...
Michael S Kelly
Michael S Kelly
Dapagliflozin is an oral agent for type 2 diabetes mellitus (T2DM) belonging to the sodium/glucose cotransporter 2 inhibitor (SGLT2-I) class of antihyperglycemic medications. In clinical trials, dapagliflozin has also been shown to reduce c...